Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
featured
A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

A phase II study of Antineoplastons A10 And AS2-1 Private In Children With Primary Malignant Brain Tumors

  • 136 views
  • 08 Nov, 2020
  • 1 location
QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

The primary objective of study CA601.2 is to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ABI-011 when administered by intravenous (IV) infusion on Days 1, 8, and 15, followed by a week of rest, in patients with advanced solid tumor malignancies or lymphomas. The …

calcium
lymphoma
metastasis
neutrophil count
advanced malignant solid tumor
  • 9 views
  • 08 Nov, 2020
  • 1 location
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

structures) and focal radiotherapy. A large number of chemotherapeutic agents (e.g. alkylating agents such as TMZ and nitrosoureas such as carmustine) have also been tested, but they display limited efficacy

alkylating agents
brain tumor
nitrosoureas
cancer
carmustine
  • 59 views
  • 17 Jan, 2021
  • 12 locations
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Background Researchers want to find better ways to treat cancer. One drug that treats cancer is paclitaxel. Sometimes proteins block that drug from working. Researchers want to see if another drug, nilotinib, helps paclitaxel work better. Objective To test the safety of nilotinib plus paclitaxel and find out what doses …

paclitaxel
metastasis
nitrosoureas
neutrophil count
cancer
  • 0 views
  • 18 Dec, 2020
  • 1 location
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

sarcoma
lymphoma
neutrophil count
adenocarcinoma
solid neoplasm
  • 0 views
  • 17 Jan, 2021
  • 1 location